Using genotyping and tissue-specific expression data from the Genotype-Tissue Expression project, researchers characterized Neanderthal allele-specific expression.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
In PLOS this week: methylation in human gametes, microRNAs linked to kidney damage in lupus patients, and more.
The company said this study marks the first time circulating RNA has been concretely linked to IFN dysregulation in lupus patients.
The firm is investing in studies that use its multiplex microarray platform to monitor lupus disease activity and traumatic brain injury response.
The firm is developing tests based on its microarray technology, which is capable of printing multiple types of biomarkers.
The meta-analysis drew on studies conducted in both European and Chinese populations, and hinted at why lupus may be more common among East Asians.
IQuity's current tests analyze gene expression patterns detected in mRNA, but the firm is also exploring the diagnostic potential of long non-coding RNAs.
The company, which also raised $14 million in a Series A round, plans to use the proceeds to commercialize panels of tests for autoimmune diseases.
The Swedish firm, a spinout of Lund University, will evaluate the array-based blood tests to confirm, rule out, and monitor the autoimmune disease.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.